

December 9, 1971

Dr. Robert Rees
SAODAP
The White House
Washington, D.C.

Dear Bob,

We are pleased to enclose a protocol for the study of l-cyclazocine-- to assess the degree of narcotic antagonism in post-addicts, and the relation of an effective 'therapeutic' dose to secondary effects. While we will be pre-occupied with our studies of naloxone pamoate during the next few weeks, we believe we can evaluate this compound concurrently, beginning about the middle of January.

This protocol will be submitted to the appropriate committees of the College for their concurrence, but we anticipate no difficulty.

Should the supplies be available, we would prefer (if there is a choice) to have l-cyclazocine presented in the same concentration and the same vehicle as racemic cyclazocine. If manufacture is no problem, we would request an initial supply of 1200 mg-- sufficient to assess the effects in 8 patients for 4-6 weeks.

Many thanks for your cooperation.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/